Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report. East African-British Medical Research Councils.
D000293:Adolescent; D000328:Adult; D000351:Africa, Eastern; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004341:Drug Evaluation; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D007538:Isoniazid / Q000494:pharmacology / Q000627:therapeutic use*; D008826:Microbial Sensitivity Tests; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D011718:Pyrazinamide / Q000627:therapeutic use*; D012008:Recurrence; D012293:Rifampin / Q000627:therapeutic use*; D013307:Streptomycin / Q000494:pharmacology / Q000627:therapeutic use*; D013828:Thioacetazone / Q000627:therapeutic use*; D013997:Time Factors; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D004338:Drug Combinations; D011718:Pyrazinamide; D013828:Thioacetazone; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin